LONG-TERM TREATMENT OF DOUBLE DEPRESSION - A PRELIMINARY-STUDY WITH SEROTONERGIC ANTIDEPRESSANTS

被引:19
作者
HELLERSTEIN, DJ
YANOWITCH, P
ROSENTHAL, J
HEMLOCK, C
KASCH, K
SAMSTAG, LW
WINSTON, A
机构
[1] BETH ISRAEL MED CTR, MOOD DISORDERS RES UNIT, NEW YORK, NY USA
[2] MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY USA
关键词
DOUBLE DEPRESSION; DYSTHYMIA; MAJOR DEPRESSION; FLUOXETINE; TRAZODONE;
D O I
10.1016/0278-5846(94)90030-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hellerstein, David J., Philip Yanowitch, Jesse Rosenthal, Camille Hemlock, Karen Kasch, Lisa Samstag and Arnold Winston: Long-Term Treatment of Double Depression: A Preliminary Study with Serotonergic Antidepressants. Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 1994, 18(1) : 139-147. 1. There is increasing evidence that many patients with major depression also have coexisting dysthymia, and that antidepressant treatment may alleviate both conditions. 2. Open-label study of fluoxetine and trazodone for 18 patients meeting DSM-III-R criteria for concurrent dysthymia and major depression. 3. Fourteen patients completed three-month medication trials, and seven (50%) of completers) responded to treatment. At five months, eight (57.1%) were in remission. Fluoxetine was significantly better tolerated than trazodone, with respective dropout rates of 7.7% and 80%. 4. Findings are consistent with efficacy of serotonergic agents in this condition.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [31] New statistical proposals to evaluate the benefit/risk ratio of long-term treatment of depression - Application to a one-year double-blind study comparing medifoxamine with fluoxetine
    Lehert, P
    Poirier-Littre, MF
    Pringuey, D
    Galinowski, A
    CLINICAL DRUG INVESTIGATION, 1998, 15 (04) : 285 - 295
  • [32] Deep brain stimulation and fluoxetine exert different long-term changes in the serotonergic system
    Voile, Julien
    Bregman, Tatiana
    Scott, Brian
    Diwan, Mustansir
    Raymond, Roger
    Fletcher, Paul J.
    Nobrega, Jose N.
    Hamani, Clement
    NEUROPHARMACOLOGY, 2018, 135 : 63 - 72
  • [33] Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study
    Shrashimirova, Milena
    Tyanev, Ivan
    Cubala, Wieslaw J.
    Wichniak, Adam
    Vodickova-Borzova, Claudia
    Ruggieri, Alessandro
    Bonelli, Annalisa
    Lipone, Paola
    Comandini, Alessandro
    Cattaneo, Agnese
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 1181 - 1193
  • [34] A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-Wide Additive Genetic Effects on Depression Severity and Treatment Response
    Palmer, Rohan H. C.
    Beevers, Christopher G.
    McGeary, John E.
    Brick, Leslie A.
    Knopik, Valerie S.
    CLINICAL PSYCHOLOGICAL SCIENCE, 2017, 5 (01) : 158 - 165
  • [35] Why does depression promote long-term opioid use?
    Sullivan, Mark D.
    PAIN, 2016, 157 (11) : 2395 - 2396
  • [36] Self-Rated Health and Long-Term Prognosis of Depression
    Ambresin, Gilles
    Chondros, Patty
    Dowrick, Christopher
    Herrman, Helen
    Gunn, Jane M.
    ANNALS OF FAMILY MEDICINE, 2014, 12 (01) : 57 - 65
  • [37] Long-term follow-up of adolescent depression. A population-based study
    Bohman, Hannes
    Jonsson, Ulf
    Paaren, Aivar
    Von Knorring, Anne-Liis
    Olsson, Gunilla
    Von Knorring, Lars
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2010, 115 (01) : 21 - 29
  • [38] Side effects of long-term treatment with fluoxetine
    Buchman, N
    Strous, RD
    Baruch, Y
    CLINICAL NEUROPHARMACOLOGY, 2002, 25 (01) : 55 - 57
  • [39] A comparative study of antidepressants opra and fluoxetine in the treatment of depression in patients with multiple sclerosis
    Ovcharov, V. V.
    Buldakova, N. Yu.
    Enikolopova, E. V.
    Boiko, A. N.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2007, : 133 - 136
  • [40] Panic disorder. A long-term treatment study: Fluoxetine vs imipramine
    Amore, M
    Magnani, K
    Cerisoli, M
    Casagrande, C
    Ferrari, G
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1999, 14 (06) : 429 - 434